HK1244012A1 - Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain - Google Patents

Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain

Info

Publication number
HK1244012A1
HK1244012A1 HK18103438.4A HK18103438A HK1244012A1 HK 1244012 A1 HK1244012 A1 HK 1244012A1 HK 18103438 A HK18103438 A HK 18103438A HK 1244012 A1 HK1244012 A1 HK 1244012A1
Authority
HK
Hong Kong
Prior art keywords
derivatives
inhibitory properties
treating bone
associated pain
bone associated
Prior art date
Application number
HK18103438.4A
Other languages
Chinese (zh)
Inventor
Adrian Walmsley
Sachin Kumar Dubey
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/562,297 external-priority patent/US20150183885A1/en
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of HK1244012A1 publication Critical patent/HK1244012A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18103438.4A 2014-12-05 2018-03-12 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain HK1244012A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/562,297 US20150183885A1 (en) 2012-06-08 2014-12-05 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP15165107 2015-04-24
PCT/EP2015/078875 WO2016087677A1 (en) 2014-12-05 2015-12-07 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain

Publications (1)

Publication Number Publication Date
HK1244012A1 true HK1244012A1 (en) 2018-07-27

Family

ID=54838344

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103438.4A HK1244012A1 (en) 2014-12-05 2018-03-12 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain

Country Status (7)

Country Link
EP (1) EP3227334A1 (en)
JP (1) JP2018505853A (en)
CN (1) CN107207599A (en)
CA (1) CA2969940A1 (en)
HK (1) HK1244012A1 (en)
MA (1) MA41097A (en)
WO (1) WO2016087677A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327963A (en) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 Ophthalmic preparation and application thereof
US20210170029A1 (en) * 2017-11-20 2021-06-10 Just-Evotec Biologies, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
AR114110A1 (en) 2018-02-28 2020-07-22 Lilly Co Eli ANTI-TRKA ANTIBODY
AU2020281378A1 (en) * 2019-05-30 2021-10-28 Sunshine Lake Pharma Co., Ltd. Anti-TrkA antibodies and uses thereof
AR122141A1 (en) 2020-05-28 2022-08-17 Lilly Co Eli TRKA INHIBITOR
WO2023125477A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkA ANTIBODY AND APPLICATION THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (en) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ITRM20030601A1 (en) * 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
EP2007814A2 (en) * 2005-05-20 2008-12-31 Ablynx N.V. Single domain vhh antibodies against von willebrand factor
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
ITRM20050332A1 (en) * 2005-06-24 2006-12-25 Lay Line Genomics Spa USE OF MOLECULES ABLE TO BLOCK TRKA'S ACTIVITY TO STRENGTHEN THE EFFECTS OF ANALGESIC OPPIACEI ON PAIN.
DK2252633T3 (en) * 2008-02-04 2013-11-11 Lay Line Genomics Spa Anti-TrkA antibodies and derivatives thereof
NZ611076A (en) * 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
MX362394B (en) * 2012-06-08 2019-01-15 Glenmark Pharmaceuticals Sa Humanized anti-trka antibodies with amino acid substitutions.

Also Published As

Publication number Publication date
EP3227334A1 (en) 2017-10-11
MA41097A (en) 2017-10-10
WO2016087677A1 (en) 2016-06-09
JP2018505853A (en) 2018-03-01
CA2969940A1 (en) 2016-06-09
CN107207599A (en) 2017-09-26

Similar Documents

Publication Publication Date Title
IL258725A (en) Cd80 extracellular domain polypeptides and their use in cancer treatment
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
EP3151797A4 (en) Methods and devices for treating the skin
IL251215B (en) Cannabinoid composition and method for treating pain
HK1244681A1 (en) Therapeutic combinations and methods for treating neoplasia
HK1231348A1 (en) Apparatus and methods for regulating cryogenic treatment
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
HK1244012A1 (en) Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain
HRP20181490T1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
ZA201704726B (en) Peptides and their use in the treatment of skin
HK1251168A1 (en) Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties
IL252904A0 (en) Methods and agents for treating disease
PL3406258T3 (en) Medicament for use in treating gout
SG11201700623YA (en) Biological treatment method and biological treatment device
IL264600B (en) Knife for use in medical treatment
GB2539742B (en) Therapeutic treatment methods, and apparatus for use therein
SG11201701939UA (en) Cosmetic and/or pharmaceutical composition in the form of a dispersion, method for preparing same and use thereof for skin treatment
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
IL255012A0 (en) Compositopns and methods for treating skin conditions
PL3262069T3 (en) Use of antibodies and antagonists directed against lrg1 in treatment
IL268265B (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer